like this model as we incur no bad debt, expand into a new market that needs all their money upfront.nothing stopping it to be leveraged into the QuickFee B2B model. ?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago